Latest Breaking News On - Remi barbier - Page 4 : comparemela.com

Cassava Sciences Appoints Three New Members to its Board of Directors

Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 Cassava Sciences, Inc. , a.

United statesEric schoenBristol myers squibbRemi barbierRobert anderson jrClaude nicaisePierre gravierServices branchStrategic developmentCassava sciencesGlobal regulatory affairs at alexion pharmaceuticalsGlobal developmentTherapeutics incCassava sciences incSenior vice presidentGlobal regulatory affairs

Cassava Sciences (SAVA) Appoints Three New Members to its Board of Directors

Cassava Sciences (SAVA) Appoints Three New Members to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pierre gravierClaude nicaiseRemi barbierRobert anderson jrBristol myers squibbCassava sciences incTherapeutics incGlobal regulatory affairs at alexion pharmaceuticalsGlobal developmentStrategic developmentServices branchCassava sciencesSenior vice presidentGlobal regulatory affairsAlexion pharmaceuticalsVice president

Cassava Sciences: How To Interpret 3 Positive Updates Shared In Q3 (NASDAQ:SAVA)

Cassava Sciences: How To Interpret 3 Positive Updates Shared In Q3 (NASDAQ:SAVA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesEli lillyHoau yan wangRichardj barryRemi barbierInternational journal of molecular sciencesCassava sciences incBiogen incDrug administrationUniversity of milanCassava sciencesAlzheimer associationCity university new yorkNew york timesYale university

Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout (NASDAQ:SAVA)

Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout (NASDAQ:SAVA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Remi barbierCassava sciencesPain therapeutics incPain therapeuticsSpecial protocol assessmentCognition maintenance studyEpisodic memorySpatial working memoryDisease assessment scale cognitiveMini mental state examinationNeurofilament light chainDisease cooperative study activitiesDaily living inventory

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer s.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected.

United statesRemi barbierEric schoenCassava sciences incCassava sciencesCassava scienceSafety monitoring boardThird quarterMore information contactChief financialNote regarding forward looking statementsPrivate securities litigation reform actAnnual reportFinancial tables follow